SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, attributed to stronger demand for Amtagvi and Proleukin, is driving the sharp rally and renewed attention to its commercial growth. Traders are broadly bullish, with some attributing the move to short covering and anticipating lung-cancer data, while others caution about a pullback or possible share dilution.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data showing slower upper-limb decline after patients switched to deramiocel is driving attention and an after-hours share jump. Many traders view the results as supportive of FDA approval, while others caution that the data may not resolve the agencys concerns over trial analysis and efficacy.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vandas positive Phase 3 results for Hetlioz in delayed sleep-wake phase disorder are driving attention, with the trial meeting its primary endpoint and the company planning to pursue an additional FDA indication. Traders are largely celebrating the readout and potential commercial opportunity, while some caution that approval and revenue impact remain uncertain.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Attention centers on Evernorths Armada SPAC combination and transition to XRPN, positioning the company as a publicly traded XRP treasury vehicle. Traders are enthusiastic about XRP-linked exposure and warrants, while others question the valuation and flag crypto volatility and SPAC-related risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is dominated by the ongoing Iran conflict, uncertainty over negotiations and the Strait of Hormuz, and concerns that elevated oil and diesel costs could weigh on markets and consumers. Reactions are sharply divided over Trumps handling of the conflict, while some traders also question DJTs business fundamentals and others post bullish calls.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp bounce has traders calling for a breakout and pointing to Zebecs payroll and payments partnerships as a longer-term adoption story. Speculation about Robinhood or BlackRock involvement is unconfirmed, and skeptics question whether the move can hold amid a history of weak follow-through.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on the August PCE inflation report and what it could mean for Treasury yields and the Feds next rate decision, with some expecting cooler data to support a rebound and others bracing for renewed selling. Rising-yield concerns and quarter-end trading are adding to the choppy price action and debate over whether the market will recover or extend its losses.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is chiefly being discussed as a broad-market, long-term buy-and-hold core, with traders praising diversification and steady accumulation. Others warn that the total-market fund remains exposed to concerns about elevated tech and AI valuations, interest rates, and broader market volatility, while some investors continue to favor buying dips.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Buyout speculation dominates, with traders pointing to BRIUMVIs commercial growth and the potential of its subcutaneous formulation and pipeline as reasons a larger pharma company might pursue TG Therapeutics. No acquisition is confirmed; bullish expectations are balanced by uncertainty around a deal and debate over valuation, while investors also watch for upcoming clinical updates.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks prolonged selloff is drawing attention amid concerns about slowing revenue growth, weak guidance, and pressure on programmatic advertising budgets, with traders also citing competition from Amazon and AI-driven changes. The community is sharply divided between bearish views that the business and management are in decline and bullish arguments that its cash generation and steep drop may leave room for a recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OpenAI Launches AI Agent 'Dots', While Reportedly Seeking A $30B Funding Bridge At $1.4 Trillion Valuation

The move appears tied to investor reaction to OpenAIs launch of Dots, a direct competitor to Metas Muse: traders focused on Dots early demo and paid-tier availability as potential support for Metas AI-agent positioning.

Mark Zuckerberg Labels It 'Significant Positive Step,' Musk Nods Yes as Trump Inks New AI Safety Deal With Top CEOs

Trump and major AI companies agreed to a voluntary pact requiring stronger safeguards, independent audits and more.read more...

Trump signs executive order rebranding AI as 'Super Intelligence' as tech titans ink separate SI accord

President Donald Trump on Tuesday signed an executive order directing the federal government to replace the term "artificial intelligence" with "Super Intelligence" across the executive branch, cementing a rebranding effort he has championed in recent weeks.Signed after a White House summit with...

Equity

OpenAI has announced a major lineup of product updates, including an always-on digital assistant named Dots, while simultaneously opening discussions to secure at least $30 billion in new private investment. 


Why Muse is Winning the Agentic AI Race

While heavyweights like OpenAI and Anthropic continue to push technological boundaries, Meta's global reach, data, and pricing power give it an edge.

GOOGL's Prospects Ride on AI Initiatives: Can It Beat RDDT and META?

Alphabet's accelerating AI adoption across Search, advertising, Cloud and Gemini strengthens its growth prospects as competition with META and RDDT intensifies.


Meta Expands Muse To Small Businesses — AI Agent Can Connect With Payments, Commerce And Productivity Tools

Meta introduced Muse earlier this month as a personal AI agent designed to work toward longer-term goals rather than simply respond to individual prompts. Muse for Small Business extends that same model into commercial workflows.

Full Transcript: Meta Platforms Q2 2026 Earnings Call

Meta Platforms (NASDAQ:META) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below.
Benzinga APIs provide real-time access toread more...

Should You Buy Meta Platforms Stock Now or Wait for a Dip?

Key PointsMeta Platforms has been investing heavily in artificial intelligence (AI) and recently launched many different subscription options related to AI...

OpenAI Teases Over 20 Launches At Developer Event As Meta’s Alexandr Wang Fires ‘Star Wars’-Inspired Jab

OpenAI faces a rapidly intensifying race across models, agents and AI-powered products.


Trump's AI Lunch Will Bring Together Mark Zuckerberg, Jensen Huang, Other Tech Bigwigs: Here's Who Else Is Invited

Trump is set to host top executives from Meta, Anthropic, OpenAI, Alphabet, Palantir and Nvidia at a White House AI lunch.read more...

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Neutral Sentiment

Meta (fb) stock price, news, financials, community insights, and trading ideas, Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

Meta Platforms Stock Price, News, Analysis and Trading Ideas

Up > 1%

Flat +/- 1%

Down > 1%

Where does the S&amp;P 500 finish next week vs. Friday’s close?

Stocktwits

Where does the S&P 500 finish next week vs. Friday’s close?

Microsoft Corp

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

Investors are closely watching the intense rivalry as Muse, Dots, and other platforms compete for AI agent market dominance.

High levels of intra-day swings and complex options positioning are causing rapid, aggressive price fluctuations.

Strategic moves into enterprise AI software and key executive talent hires are polarizing analysts on the firm's long-term monetization.

Traders are intensely monitoring a potential golden cross and multi-year resistance levels near the 750 mark for a breakout.

Recent high-profile industry meetings with government leaders are fueling speculation over future AI oversight and regulatory frameworks.

Current Price	$738.79
Prev Close	$715.62
Open	$725.00
Dividend Yield	0.32%
50-Day Moving Average	$619.00
Beta	1.45
Avg. Volume	15.9M
PE Ratio	27.83

52-Week High	$779.82
52-Week Low	$520.26
Market Capitalization	$1.82T
EPS (Annual)	$23.49
Price to Book	7.21
Revenue Per Employee	$2.55M

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

META Fundamentals